<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    Why did Crinetics' operating expenses surge in Q4 2024?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        5/8/2025 09:31pm
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Crinetics Pharmaceuticals experienced a significant increase in operating expenses in Q4 2024, primarily due to higher personnel costs and development activities. 

The company's ongoing clinical programs and preparations for the potential commercial launch of paltusotine contributed to the rise in research and development expenses. Additionally, the strengthening of their leadership team and strategic vision for growth also impacted the operating expenses.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao){return {layout:"default",data:[{noData:c,currentQuestion:d,textDescription:E,comeFrom:"AInvestShareLink",events:[],answerSource:l}],fetch:{},error:m,state:{sharePreviewModule:{loadJgySuccess:g,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:l,cache_builder:a,reply_action:"Answer",execute_mode:w,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"Why did Crinetics' operating expenses surge in Q4 2024?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"Why did Crinetics' operating expenses surge in Q4 2024?\",\"user_id\":\"dp53799879\",\"user_name\":\"\",\"trace_id\":\"5c26698f-dd96-4fc5-bfaf-f002f373c59f\",\"session_id\":\"5c26698f-dd96-4fc5-bfaf-f002f373c59f\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:"search",raw_data:{number:F,title:G,summary:H,full_summary:"Crinetics Pharma ( (CRNX) ) has released its Q4 earnings. Here is a breakdown of the information Crinetics Pharma presented to its investors. Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company specializing in developing novel therapeutics for endocrine diseases and endocrine-related tumors. The company is known for its innovative oral, small-molecule drug candidates, including paltusotine and atumelnant, which target conditions such as acromegaly, carcinoid syndrome, and congenital adrenal hyperplasia. In its latest earnings report, Crinetics Pharmaceuticals highlighted significant progress in 2024, including the acceptance of its New Drug Application for paltusotine by the FDA and the strengthening of its leadership team. The company also reported a strong financial position with $1.4 billion in cash, providing a runway into 2029. Key financial metrics revealed increased research and development expenses, which rose to $240.2 million for the full year 2024, up from $168.5 million in 2023, primarily due to higher personnel costs and development activities. The net loss for 2024 was $298.4 million, compared to $214.5 million in 2023. Despite these losses, Crinetics maintains a robust cash position, bolstered by significant equity financing and public offerings. Looking ahead, Crinetics is poised for a transformative year in 2025, with plans to initiate multiple late-stage and early-stage trials. The company is preparing for the potential commercial launch of paltusotine, pending FDA approval, and aims to advance its development pipeline with several new investigational drug filings. Crinetics Pharmaceuticals remains focused on executing its strategic vision, leveraging its strong financial foundation and leadership team to drive growth and innovation in the endocrine therapeutics space. Trending Articles:",url:I,image_url:a,video_url:a,publish_time:J,search_extra_info:{search_burial_info:{id:x,uid:K,ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]}}},simhash:"7288b0d2ec4ac5e",msg_id:x}}],answer_chain_name:O,agent_mode:P,native_answer:a,come_from:a,text_answer:E,trace_id:f,cost:18414,event_names:a,question:d,fallback_type:Q,input_type:R,fall_back_reason:{fall_back_type:Q,may_fall_back_reason:"UNKNOWN",risk_detail:{matched_words:[]}},session_id:f,first_return_cost:4150,cache_type:"no_cache",question_id:f,transfer_question:d,signal_type:"ON_COMPLETE",start_time:y,remote_svc:l,slots:[],answer_type:w,user_id:r,skill_name:z},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:f,session_id:f,user_id:r,question:d,source:l,raw_question:d,version:"3.4.1",action_name:z,nlu:{entity:[{type:S,value:"CRNX.O",market:T}]},output_time:y,deep_research:c,deep_thinking:c,agent_mode:P},extra:{}},{answer_path:h,section:{id:i,info_texts:["Thinking"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: CRNX Latest Report Period"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:A},logs:[],extra:{action:U,action_input:"CRNX Latest Report Period",thought:"The user wants to analyze why Crinetics' operating expenses increased significantly in Q4 2024. I should focus on Crinetics' latest report period to obtain the relevant data and information. I will use FinQuery for the latest report period. Then, based on the identified latest report period, I will use FinQuery for the operating expenses data and search for the analysis of operating expenses increase in Q4 2024."}},{answer_path:e,section:{id:B,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:h,section:{id:i,info_texts:["Querying Stock: CRNX Operating Expenses in Fiscal 2024Q4"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:A},logs:[],extra:{action:U,action_input:"CRNX Operating Expenses in Fiscal 2024Q4",thought:V}},{answer_path:h,section:{id:i,info_texts:["Searching Web: Crinetics Operating Expenses Increase Analysis in Fiscal 2024Q4"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:A},logs:[],extra:{action:"Searching Web",action_input:"Crinetics Operating Expenses Increase Analysis in Fiscal 2024Q4",thought:V}},{answer_path:e,section:{id:B,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:B,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:h,section:{id:i,info_texts:["Generating Answer"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:e,section:{id:t,info_texts:[],show_type:u,voice_txt:"Cr",text_answer:W,rich_text:W,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:2000,info_texts:[],show_type:u,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:I,image_url:a,video_url:a,title:G,summary:H,index:F,publish_time:J,search_id:x,search_uid:K,search_ab:{scene_id:L,layer_exp:[{layer_id:M,exp_id:N}]},jump_type:"normal"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:t,info_texts:[],show_type:u,voice_txt:". \n\n",text_answer:X,rich_text:X,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"CRNX",market_id:T,name:Y,domain:S},pos:g,section_id:t,txt:Y,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:e,section:{id:t,info_texts:[],show_type:u,voice_txt:" company",text_answer:Z,rich_text:Z,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:h,section:{id:i,info_texts:["Completed"],show_type:j,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:n,query_text:n,trace_info:{item_id:"cb3987ab3349cecc3ad7af70beff30bf",item_type:k,item_name:n,rec_info:_}},{display_text:o,query_text:o,trace_info:{item_id:"1578ebe12fdc31c3b18c8d92e85c3efd",item_type:k,item_name:o,rec_info:$}},{display_text:p,query_text:p,trace_info:{item_id:"8d6a993b001f8abb8afb5ce0eee9ab60",item_type:k,item_name:p,rec_info:aa}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:g,type:"1",display2:c,url:a}},request_config:[{source_type:ab,related_name:ac}],puuid:C,tag:a,category:"custom",uuid:ad}],global:{urp_static_data:[{name:ac,value:{status_code:g,columns:[{type:q,index_name:ae,key:ae},{type:q,index_name:af,key:af},{type:q,index_name:ag,key:ag},{type:q,index_name:ah,key:ah},{type:q,index_name:ai,key:ai}],datas:[{send_text:n,item_type:k,rec_info:_,display_text:n,rec_reason:a},{send_text:o,item_type:k,rec_info:$,display_text:o,rec_reason:a},{send_text:p,item_type:k,rec_info:aa,display_text:p,rec_reason:a}],dataSize:ab,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:aj,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:v,"min-height":"100%",position:ak,height:v},isMaterial:c,id:aj,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:g,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:D,componentUuid:ad,script:[{name:al,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:D,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:D},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:v,position:ak,height:v},isMaterial:b,_id:19,id:al,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:am,voice_txt:a,tracking_info:{},uuid:C},order:{is_auto:c,render_for:am,chart_type:"command",puuid:C}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1003,info_texts:[],show_type:s,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:z,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:w,answer_chain_name:O},is_deep_research:c,deep_thinking:c,create_time:1746711137971},is_last:b}],questionItem:{data:{qStr:d,encodeFlag:c,imageData:m,docsData:[],quoteData:m},tplType:"question"},events:an,agentId:a,param:{entity_info:{},add_info:{ori_question:d},event_list:an,client_ip:a,question:d,user_id:r,user_name:a,trace_id:f,session_id:f,source:l,input_type:R}}],userId:r,userName:a,startTime:y,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:m,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:g,traceTableData:m,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fwhy-did-crinetics-operating-expenses-surge-in-q4-2024-2f84b5\u002F",config:{_app:{basePath:ao,assetsPath:ao,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"Why did Crinetics' operating expenses surge in Q4 2024?","other\u002FopenAnswer","5c26698f-dd96-4fc5-bfaf-f002f373c59f",0,"progress\u002Fsearching_for",1000,"searching_for","llm_generated","ths_ainvest_lite_web",null,"Has Crinetics announced any changes in management or leadership that could impact operating expenses?","What is the current market sentiment towards Crinetics' stock and how might it relate to the recent surge in operating expenses?","Are there any recent developments in Crinetics' product pipeline that could explain the increase in operating expenses?","STR","dp53799879","signal",2001,"rich_text","auto","agent","bad4f6619c13a1d4_0",1746711119558,"explain news events","thinking",999,"39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Crinetics Pharmaceuticals experienced a significant increase in operating expenses in Q4 2024, primarily due to higher personnel costs and development activities. \n\nThe company's ongoing clinical programs and preparations for the potential commercial launch of paltusotine contributed to the rise in research and development expenses. Additionally, the strengthening of their leadership team and strategic vision for growth also impacted the operating expenses.",7,"Crinetics Pharmaceuticals: Financial Results and Future Plans","Crinetics Pharma ( (CRNX) ) has released its Q4 earnings. Here is a breakdown of the information Crinetics Pharma presented to its investors. Crinetics Pharmaceuticals is a clinical-stage pharmaceutical company specializing in developing novel therapeutics for endocrine diseases and endocrine-relate...","https:\u002F\u002Fwww.tipranks.com\u002Fnews\u002Fcompany-announcements\u002Fcrinetics-pharmaceuticals-financial-results-and-future-plans","2025-02-28","bad4f6619c13a1d4","oeqxkhszf","oeqxkhszf_layer","base","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite","stock","185","Querying Stock","I have obtained the latest report period of Crinetics is 2024Q4. Now I will use FinQuery to obtain the operating expenses data in 2024Q4 and use Search to find the analysis of operating expenses increase in Q4 2024.","Crinetics Pharmaceuticals experienced a significant increase in operating expenses in Q4 2024, primarily due to higher personnel costs and development activities[^7]",". \n\nThe","Crinetics"," company's ongoing clinical programs and preparations for the potential commercial launch of paltusotine contributed to the rise in research and development expenses. Additionally, the strengthening of their leadership team and strategic vision for growth also impacted the operating expenses.","2+679_496_21_554+0+0+5c26698f-dd96-4fc5-bfaf-f002f373c59f+cb3987ab3349cecc3ad7af70beff30bf+llm_generated+aimeTagAnalysis+0+0.01051379181444645+1","2+679_496_21_554+0+0+5c26698f-dd96-4fc5-bfaf-f002f373c59f+1578ebe12fdc31c3b18c8d92e85c3efd+llm_generated+aimeTagAnalysis+0+0.00476838368922472+2","2+679_496_21_554+0+0+5c26698f-dd96-4fc5-bfaf-f002f373c59f+8d6a993b001f8abb8afb5ce0eee9ab60+llm_generated+aimeTagAnalysis+0+0.003913440275937319+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>